Selectin and selectin ligand binding: a bittersweet attraction
Thomas M. Zollner, Khusru Asadullah
Thomas M. Zollner, Khusru Asadullah
Published October 1, 2003
Citation Information: J Clin Invest. 2003;112(7):980-983. https://doi.org/10.1172/JCI19962.
View: Text | PDF
Commentary

Selectin and selectin ligand binding: a bittersweet attraction

Abstract

Inhibition of leukocyte migration into target organs has long been an attractive, though challenging, basis for anti-inflammatory strategies. However, to date, the manipulation of leukocyte rolling along blood vessels has not yielded successful new therapies. An important study may now open new avenues in this exciting field of anti-inflammatory therapies by introducing a putative inhibitor of poly-N-acetyllactosamine biosynthesis that affects selectin ligand activity and shows efficacy in a rodent skin inflammation model.

Authors

Thomas M. Zollner, Khusru Asadullah

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
The multistep process of the interactions between lymphocytes and endoth...
The multistep process of the interactions between lymphocytes and endothelial cells leading to T cell migration into skin. Selectin and selectin ligand interactions allow lymphocyte rolling along the endothelial lining. Lymphocyte chemokine receptors thereby come into contact with chemokines displayed by the endothelium; e.g., via proteoglycans leading to activation of integrins. This is necessary for subsequent firm adhesion of lymphocytes to the endothelium and the final transmigration through the blood vessel wall. VLA-4, very late antigen-4.